News | November 11, 2024
Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Aims to achieve CDMO sales of US$ 400 million by 2028
The state-of-the-art facility is equipped with best-in-class equipment and control systems
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line
With more than 35 years of experience, Best Formulations is the largest manufacturer of plant-based softgels in the United States, with newly expanded capabilities for nutritional gummies and personal care
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Subscribe To Our Newsletter & Stay Updated
